MedTrace Logo

Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

NCT07068490 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100000

Last updated 2025-07-16

No results posted yet for this study

Summary

Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.

Conditions

Interventions

DRUG

Routine use of P-CAB on DAPT

This group received P-CAB with DAPT after PCI.

DRUG

Guideline Directed Medical Therapy

This group received PPI or not with DAPT after PCI according to GI bleeding risk.

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • KI HONG CHOI, MD, PhD · Samsung Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-22
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07068490 on ClinicalTrials.gov